GlassScriptPhysician profile
Kendall S Hash
NPI 1154302826
$6,483.40
in general payments reported to CMS, 2019-2025
37 companies · $1,611 in 2025
The $1,611 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,074 · 2020: $404 · 2021: $22.01 · 2022: $675 · 2023: $1,335 · 2024: $1,363 · 2025: $1,611.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,214 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,213.85 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,335.28 | 2019-2025 | |
| Amgen INC. | $549.97 | 2020-2025 | Otezla |
| Sun Pharmaceutical Industries INC. | $508.64 | 2019-2025 | Ilumya, Absorica Ld, Winlevi |
| Genzyme Corporation | $482.69 | 2019-2025 | |
| Leo Pharma INC. | $400.09 | 2019-2025 | Adbry |
| Janssen Biotech, INC. | $359.43 | 2023-2025 | Tremfya, Simponi, Simponi Aria |
| Ucb, INC. | $324.20 | 2019-2025 | Bimzelx, Cimzia |
| Novartis Pharmaceuticals Corporation | $296.91 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $287.01 | 2019-2025 | Dupixent, Libtayo |
| Lilly USA, LLC | $214.05 | 2019-2025 | Ebglyss, Taltz |
| Mayne Pharma Commercial LLC | $202.93 | 2019-2020 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $184.17 | 2019-2023 | Arazlo |
| E.R. Squibb & Sons, L.L.C. | $155.54 | 2024-2025 | Sotyktu |
| Pfizer INC. | $145.49 | 2019-2025 | |
| Incyte Corporation | $139.32 | 2023-2025 | Opzelura |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $136.78 | 2019-2025 | Nemluvio |
| Almirall LLC | $103.26 | 2019-2023 | Klisyri |
| Dermavant Sciences, INC. | $88.06 | 2023-2024 | Vtama |
| Biofrontera INC. | $87.46 | 2019-2025 | Xepi, Bf-Rhodoled, Ameluz |
| Arcutis Biotherapeutics, INC. | $85.36 | 2023-2025 | Zoryve |
| Organon LLC | $67.64 | 2025 | Vtama |
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.67 | 2023 | Spevigo |
| Celgene Corporation | $37.46 | 2019 | |
| Nobelpharma America, LLC | $23.15 | 2025 | |
| Epi Health, LLC | $21.57 | 2022 | |
| Vyne Pharmaceuticals INC. | $21.08 | 2020 | |
| Mylan Institutional INC. | $20.55 | 2023 | Hulio |
| Lnhc, INC | $18.83 | 2025 | Zelsuvmi |
| Taro Pharmaceuticals USA, INC. | $18.29 | 2019 | |
| Sandoz INC. | $17.07 | 2024 | Hyrimoz |
| Dusa Pharmaceuticals, INC. | $16.63 | 2019 | |
| Aclaris Therapeutics, INC. | $15.81 | 2019 | |
| Sebela Pharmaceuticals INC. | $15.74 | 2020 | |
| Organogenesis INC. | $13.87 | 2025 | Via Matrix |
| Mylan Pharmaceuticals INC. | $13.71 | 2019 | |
| Journey Medical Corporation | $13.57 | 2025 | |
| Allergan, INC. | $12.12 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kendall Hash listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.